Jean‐Michel Molina

机构：Université Paris Cité, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Lariboisière, Hôpital Saint-Louis · ORCID：0000-0001-8684-2214

发表论文 920 篇 · 总被引 38274 次 · h-index 93

代表论文

• Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial (2025 · The Lancet Infectious Diseases · 被引 24)
• Innovations in the biomedical prevention, diagnosis, and service delivery of HIV and other sexually transmitted infections (2025 · The Lancet · 被引 20)
• Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial (2025 · Clinical Infectious Diseases · 被引 12)
• Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial (2025 · Clinical Infectious Diseases · 被引 10)
• Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process (2025 · The Lancet HIV · 被引 10)
• Beyond behavioural change: prioritising structural solutions to control bacterial sexually transmitted infections (2025 · EClinicalMedicine · 被引 8)